Today, Pharmaxo announces it is joining Icon Group – operator of integrated cancer care centres throughout Australia, South East Asia and the UK and owner of Slade Health, a specialist compounding operator across Australia and New Zealand.

Icon plays a major and critical role in chemotherapy compounding supply to both private and public healthcare sectors in Australia. Slade has experienced exponential growth in the last eight years and today delivers over 1.2 million infusions annually.

Pharmaxo, which employees over 400 people in the South West, is a leading pharmaceutical specialist manufacturer (Bath ASU) and clinical homecare provider (Pharmaxo Healthcare), based in Corsham, Wiltshire.

This partnership marks the establishment of a global compounding operator and Icon’s pharmaceutical entry in the United Kingdom, underscoring a commitment to improving healthcare in the region.

It marks the next step in Icon’s growth in the UK, complementing their strategic partnership with Nuffield Health to bring more cancer treatment capacity to underserved communities across the UK.

Chris Watt, Executive Chair of Pharmaxo Group explains:

“For 20 years Bath ASU has been at the heart of the UK compounding sector through shaping the development of chemotherapy dose banding, establishing validated technical training delivered at universities and setting out the standards the NHS now uses to assess the stability of complex biological medicines.”

“We are now at a stage where global scale matters. We believe we can achieve more, and can continue to shape our industry, by joining forces with Icon Group.”

Icon Group CEO, Mark Middleton said this move reflects Icon’s proven model of entering new markets and a commitment to bringing comprehensive integrated healthcare to where it’s needed. It builds on the Group’s compounding excellence which is delivered under the Slade Health (Slade) brand in Australia and New Zealand.

“Welcoming Pharmaxo to Icon Group reflects our ongoing commitment to improving access to world-class healthcare in the UK,” said Mark.

“Cancer rates continue to rise and there is a significant need to increase manufacturing of cancer drugs to address growing care gaps.

“Pharmaxo has built a solid foundation for growth. Combined with Icon’s strong 60-year track record in pharmaceuticals and sterile compounding under the Slade Health brand, together we will continue bringing the latest drugs to where people need them in the UK, eliminating unnecessary travel and ensuring timely access to life-saving medications.”

Pharmaxo Group CEO, Ian Muir said they were impressed by Icon’s compounding capabilities.

“Icon and Slade share our commitment to quality customer service and patient-centred care. Their extensive experience and reputation reflect a true dedication to the highest quality manufacturing of specialised pharmaceuticals,” said Ian.
“Icon has a strong growth pipeline in the UK and Europe, and we look forward to being part of this vision and improving access to medications across the country.”

As part of the business transition, Ian Muir will remain as CEO reporting into Icon Group’s global structure. Chris Watt will serve as a strategic advisor to Icon Group on European strategy. Richard Wastnage will advise the UK operations on commercial matters.

Contact us

For all enquires please contact us by clicking here.